Ya-ting Chen, PhD

Articles by Ya-ting Chen, PhD

Adherence to Osteoporosis Medications After Patient and Physician Brief Education: Post Hoc Analysis of a Randomized Controlled Trial

ByAimee Der-Huey Shu, MD,Margaret R. Stedman, MPH,Jennifer M. Polinski, MPH, MS,Saira A. Jan, MS, PharmD,Minal Patel, MD, MPH,Colleen Truppo, RN, MBA,Laura Breiner, RN, BSN,Ya-ting Chen, PhD,Thomas W. Weiss, DrPH,Daniel H. Solomon, MD, MPH

July 7th 2009

Post hoc analysis of a randomized controlled trial found that a 1-session educational intervention targeted at patients and primary care physicians did not improve osteoporosis medication adherence.

Interactive Voice Response Telephone Calls to Enhance Bone Mineral Density Testing

ByJennifer M. Polinski, MPH,Amanda Patrick, MS,Colleen Truppo, RN, MBA,Laura Breiner, RN BA,Ya-ting Chen, PhD,Cathy Egan, RN MPH,Saira Jan, PharmD,Minal Patel, MD,Thomas W. Weiss, DrPH,Daniel H. Solomon, MD, MPH

June 1st 2006

Variations in and Correlates of Length of Stay in Academic Hospitals among Patients with Heart Failure Resulting from Systolic Dysfunction

ByHarlan M. Krumholz, MD,Ya-ting Chen, PhD,W. David Bradford, PhD,Julie Cerese, RN, MSN

June 1st 1999

Trends in Costs of Percutaneous Transluminal Coronary Angioplasty

ByAsefeh Heiat, MD,Jennifer A. Mattera, MPH,Glen A. Henry, MD,Ya-ting Chen, PhD,Harlan M. Krumholz, MD

December 1st 1998

Ya-ting Chen, PhD

Articles by Ya-ting Chen, PhD

Adherence to Osteoporosis Medications After Patient and Physician Brief Education: Post Hoc Analysis of a Randomized Controlled Trial

Interactive Voice Response Telephone Calls to Enhance Bone Mineral Density Testing

Variations in and Correlates of Length of Stay in Academic Hospitals among Patients with Heart Failure Resulting from Systolic Dysfunction

Trends in Costs of Percutaneous Transluminal Coronary Angioplasty

Latest Updated Articles

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access